Tuesday, 28 February, 2012
ethris licenses technologies for innovative nucleic acid therapy
CeNS Spin-off inventions licensed by BayPat
The Bayerische Patentallianz GmbH, the central patent and marketing agency for 28 Bavarian universities and universities of applied sciences, has licensed a number of inventions from the Ludwig-Maximilians-Universität Munich (LMU) to ethris GmbH, an up-and-coming biotechnology company. The inventions provide a basis for the development of innovative nucleic acid pharmaceuticals and for magnetic field-driven active substance transport.
The advantage of the ethris nucleic acid therapy is that the agents introduced into the body are activated via the patients themselves. Moreover, our approach has huge diversification potential. For example, a variety of diseases could be treated in the future through specific modifications of the nucleic acid building blocks, according to PD Dr. Carsten Rudolph, CEO of ethris GmbH.